Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

Movement Disorders : Official Journal of the Movement Disorder Society
Daniel Tarsy, R J Baldessarini

Abstract

Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies ...Continue Reading

References

Nov 1, 1978·The American Journal of Psychiatry·G GardosDaniel Tarsy
Sep 1, 1977·Acta Neurologica Scandinavica·P J Delwaide, M Desseilles
Jul 1, 1992·The American Journal of Emergency Medicine·J Franaszek
Mar 14, 1991·The New England Journal of Medicine·R J Baldessarini, F R Frankenburg
May 1, 1991·The American Journal of Psychiatry·V Khot, R J Wyatt
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·J H Friedman, M Ambler
Jun 1, 1986·Journal of Health and Social Behavior·P Brown, S C Funk
Sep 1, 1987·The American Journal of Psychiatry·P J WeidenA Frances
Dec 1, 1980·Archives of General Psychiatry·J M Smith, R J Baldessarini
Apr 1, 1982·Archives of General Psychiatry·John M Kane, J M Smith
Jun 1, 1983·Clinical Neuropharmacology·Daniel Tarsy
Apr 1, 1981·The British Journal of Psychiatry : the Journal of Mental Science·K Abe, T Masui
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Jun 1, 1994·The American Journal of Psychiatry·G GardosC Conley
Jun 1, 1994·Biological Psychiatry·M Davé
Sep 1, 1996·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·V S Anand, M J Dewan
Nov 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·D J Feeney, W Klykylo
Jan 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·K A Gwinn, J N Caviness
Sep 20, 1997·Acta Psychiatrica Scandinavica·Jim van OsR Murray
Oct 24, 1997·The British Journal of Psychiatry : the Journal of Mental Science·W S FentonT H McGlashan
Mar 10, 1998·The Journal of Clinical Psychiatry·B M Saran
Apr 30, 1998·Pharmacopsychiatry·C Silberbauer
Oct 15, 1998·The Journal of Clinical Psychiatry·J D Sherr, G Thaker
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJohn M Kane
May 1, 1999·Acta Psychiatrica Scandinavica·Jim van OsS G Thompson
Jun 1, 1999·Journal of Clinical Psychopharmacology·M Campbell
Jun 12, 1999·Journal of the American Geriatrics Society·D V JesteM P Caligiuri
Jul 3, 1999·Annals of Internal Medicine·A Herrán, J L Vázquez-Barquero
Aug 24, 1999·The Journal of Clinical Psychiatry·N B CarrollR T Strickland
Aug 25, 1999·Lancet·L Vercueil, J Foucher
Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E S Molho, S A Factor
Oct 13, 1999·The American Journal of Psychiatry·E Dunayevich, S M Strakowski
Dec 10, 1999·The American Journal of Psychiatry·M E Jaffe, G M Simpson
Feb 9, 2000·The Journal of Clinical Psychiatry·J Ananth, J Kenan
Apr 25, 2000·Postgraduate Medical Journal·S Kumar, D M Malone
Aug 12, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·C Lore
Aug 25, 2000·Pharmacopsychiatry·D P Bassitt, L de Souza Lobo Garcia
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, Richard S E Keefe
Mar 14, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·T G SchulzeM Rietschel
Jun 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·S Ipekçi, S Birsöz
Jul 20, 2001·Journal of Psychiatric Research·I D GlickR J Hu
Oct 2, 2001·The American Journal of Psychiatry·S Nassir Ghaemi, J Y Ko
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
Jan 26, 2002·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·D I GunalS Aktan
May 23, 2002·Clinical Neuropharmacology·S A Factor
Aug 3, 2002·The American Journal of Psychiatry·Klara J RosenquistS Nassir Ghaemi
Aug 13, 2002·Journal of Clinical Psychopharmacology·Franco Benazzi
Nov 2, 2002·The American Journal of Psychiatry·Franca CentorrinoR J Baldessarini
Nov 2, 2002·The American Journal of Psychiatry·Eiji SuzukiHitoshi Miyaoka
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie
Aug 2, 2003·Schizophrenia Research·Patrick W CorriganGregory A Toombs
Nov 25, 2003·The Journal of Neuropsychiatry and Clinical Neurosciences·Marc ZiegenbeinStefan Kropp
Nov 25, 2003·The Journal of Clinical Psychiatry·Piet P OosthuizenN Keyter
Dec 31, 2003·Molecular Psychiatry·J Licinio
Jan 2, 2004·The American Journal of Psychiatry·Martin E KeckFlorian Holsboer
Mar 18, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Dirk Dressler
Apr 2, 2004·The American Journal of Psychiatry·Hower Kwon
Apr 27, 2004·Journal of Psychopharmacology·Rodrigo A BressanLyn S Pilowsky
May 4, 2004·The Journal of Clinical Psychiatry·Jean-Pierre LindenmayerMiranda H Chakos
May 15, 2004·Journal of Child and Adolescent Psychopharmacology·Fatma CharfiPhilippe Mazet
Jun 17, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Nadeem H Bhanji, Howard C Margolese
Jul 20, 2004·Drugs·Tracy Swainston Harrison, Caroline M Perry
Sep 15, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Sherif Karama, Samarthji Lal
Nov 24, 2004·The Journal of Clinical Psychiatry·John M KaneJohn W Newcomer
Dec 14, 2004·CNS Drug Reviews·Marilyn A DaviesBryan L Roth
Jun 22, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David M GardnerPaul Waraich

Citations

Apr 27, 2011·Current Psychiatry Reports·Vladimir Lerner, Chanoch Miodownik
Oct 15, 2009·Neurotoxicity Research·Ricardo S OsorioT Palomo
Jan 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Aoi SyuTadao Arinami
Feb 25, 2009·The Pharmacogenomics Journal·C C ZaiJ L Kennedy
Jan 27, 2011·The Pharmacogenomics Journal·Arun K TiwariJ L Kennedy
Jul 27, 2007·The New England Journal of Medicine·Robert J Heine, Robert Brodows
Feb 7, 2007·Current Opinion in Psychiatry·Gary Remington
Apr 7, 2010·Drug Design, Development and Therapy·Silvio CacciaAlessandro Nobili
Nov 21, 2007·Clinical Drug Investigation·Ozcan Uzun, Ali Doruk
Mar 23, 2011·Internal Medicine·Noboru Imai, Masako Ikawa
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Sep 8, 2010·The Journal of Clinical Psychiatry·Stanley N CaroffCATIE Investigators
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudS A Factor
Jul 6, 2014·Clinical Neuropharmacology·Min-Jing LeeYu Lee
Oct 9, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Heather RigbyMandar Jog
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 16, 2011·Harvard Review of Psychiatry·Joseph Stoklosa, Dost Öngür
Jul 19, 2013·Clinical Neuropharmacology·Carrie N MoseleyMaria C Catalano
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Robert A RosenheckJ A Lieberman
Sep 10, 2014·Expert Opinion on Drug Safety·Giovanni FalisiRaul Quezada Arcega
Jun 4, 2008·Expert Opinion on Pharmacotherapy·Praveen Dayalu, Kelvin L Chou
Sep 4, 2008·Expert Opinion on Emerging Drugs·Ofer AgidGary Remington
Sep 1, 2009·Clinical Neurology and Neurosurgery·Bernardo de Mattos VianaFrancisco Eduardo Costa Cardoso
Jun 27, 2009·Neurologic Clinics·Joohi Jimenez-Shahed
Jan 6, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Young-Min ParkJae-Hyuck Cho
Jul 8, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Seung-Gul KangLeen Kim
Feb 5, 2008·Schizophrenia Research·Rajiv TandonSection of Pharmacopsychiatry, World Psychiatric Association
Aug 28, 2007·The Psychiatric Clinics of North America·P J WeidenMichael Grody
Jul 7, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasRossetos Gournellis
Jan 29, 2008·Journal of Clinical Pharmacology·Christopher KenneyJoseph Jankovic
Apr 5, 2013·The European Journal of Neuroscience·Souha MahmoudiDaniel Lévesque
Sep 8, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Sierra PeñaJoseph Jankovic
Aug 7, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·James T TeoK P Bhatia
Dec 19, 2015·Proteomics. Clinical Applications·Juliana S CassoliDaniel Martins-de-Souza
May 23, 2014·Expert Opinion on Pharmacotherapy·Leora L Borek, J H Friedman
Jul 10, 2010·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·Jan FrölichGerd Lehmkuhl
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Na-Ri Kang, Moon-Doo Kim
May 23, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Rakesh Goyal, Salam Hemabati Devi
Sep 11, 2013·Journal of Psychiatric Research·Clement C ZaiJ L Kennedy
Apr 29, 2016·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Satyakam Mohapatra
Nov 4, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Gianluca TrifiròGiovanni Gambassi
Sep 2, 2016·Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater·W Wolfgang FleischhackerKlaus Seppi
Feb 17, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Clement C ZaiJ L Kennedy
Mar 16, 2017·Journal of Psychiatric Practice·Matthew MacalusoSheldon H Preskorn
Feb 1, 2017·Journal of Clinical Psychopharmacology·Thierry Q MentzelGenetic Risk and Outcome of Psychosis (GROUP) Investigators
Jul 26, 2017·Clinical Schizophrenia & Related Psychoses·Oliver Freudenreich, Gary Remington
May 4, 2016·Therapeutic Advances in Psychopharmacology·Musa U UmarAsmaul H Abba
May 3, 2011·Journal of Clinical Psychopharmacology·R J Baldessarini, David M Gardner
May 6, 2008·Journal of Clinical Psychopharmacology·P J WeidenCurt D Wolfgang
Apr 17, 2007·Pharmacoepidemiology and Drug Safety·Sigal KaplanGerald J Dal Pan
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Robert A Rosenheck
Jun 6, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Rajaprabhakaran RajarethinamMatcheri Keshavan
Jan 18, 2018·Clinical Schizophrenia & Related Psychoses·Michael A CummingsStephen M Stahl
Jun 11, 2009·Journal of Clinical Psychopharmacology·Codrin LunguDaniel Tarsy
Feb 6, 2019·Current Opinion in Psychiatry·Christian G Widschwendter, Alex Hofer
May 16, 2018·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Davide MartinoTamara M Pringsheim
Mar 20, 2019·Future Medicinal Chemistry·Giuseppe DeganuttiChristopher A Reynolds
May 10, 2017·Clinical Drug Investigation·Gabriele SaniLeonardo Tondo
Oct 5, 2018·Frontiers in Pharmacology·Clement C ZaiJ L Kennedy
Jun 4, 2020·Practical Neurology·Eoin MulroyK P Bhatia
Jul 30, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Jeane Binotto ReinheimerRoselei Fachinetto
Jul 1, 2010·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Clement C ZaiJ L Kennedy
Oct 14, 2008·Experimental Biology and Medicine·Meeta PatnaikCarol R Reed
Apr 22, 2018·Molecular Psychiatry·R J BaldessariniGustavo H Vázquez
Oct 26, 2018·Drugs & Aging·Carlos Estevez-FragaJose Luis López-Sendón Moreno
Sep 22, 2020·Journal of the Chinese Medical Association : JCMA·Chun-Yu ChenJong-Ling Fuh

Related Concepts

Schizophrenia
Antipsychotic Effect
Pseudoakathisia

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here